# Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

> **NCT02218697** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 357 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influsplit™ Tetra (Fluarix™ Tetra)
- **BIOLOGICAL:** Pneumovax™ 23
- **BIOLOGICAL:** Placebo (Saline)

## Key facts

- **NCT ID:** NCT02218697
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-01
- **Primary completion:** 2015-01-14
- **Final completion:** 2015-05-04
- **Target enrollment:** 357 (ACTUAL)
- **Last updated:** 2018-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218697, "Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02218697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*